Shipping services continue despite COVID-19 outbreak ! Click here to view COVID-19 related products

Doramapimod (BIRB 796)

For research use only.

Catalog No.S1574

76 publications

Doramapimod (BIRB 796) Chemical Structure

CAS No. 285983-48-4

Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with Kd of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 294 In stock
USD 147 In stock
USD 270 In stock
USD 470 In stock
USD 1470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Doramapimod (BIRB 796) has been cited by 76 publications

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with Kd of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.
Features The first p38 MAPK inhibitor to be tested in a phase III clinical trial.
Targets
JNK2 [1]
()
c-RAF [1]
()
Fyn [1]
()
p38α [1]
(Cell-free assay)
p38α [7]
()
0.1 nM(Kd) 38 nM
In vitro

BIRB 796 shows no significant inhibition to ERK-1, SYK, IKK2β, ZAP-70, EGF receptor kinase, HER2, protein kinase A (PKA), PKC, PKC-α, PKC-β (I and II) and PKC-γ. BIRB 796 greatly improves binding affinity by forming a hydrogen bond between the morpholine oxygen and the ATP-binding domain of p38α. BIRB 796 represents one of the most potent and slowest dissociating inhibitors against human p38 MAP kinase now known. [1] BIRB 796 potently inhibits c-Raf-1 and Jnk2α2 with IC50 of 1.4 and 0.1 nM, respectively. [2] BIRB796 also inhibits the activity and the activation of SAPK3/p38γ at a higher concentration than it does in p38α. BIRB796 blocks the stress-induced phosphorylation of the scaffold protein SAP97, which is a physiological substrate of SAPK3/p38γ. BIRB796 blocks JNK1/2 activation and activity in HEK293 cells, while not inhibits the activation and activity of ERK1/ERK2 in Hela cells. Moreover, the binding of BIRB796 to the p38 MAPKs or JNK1/2 is impairing their phosphorylation by the upstream kinase MKK6 or MKK4 rather than enhancing their dephosphorylation. [3] BIRB 796 blocks baseline and bortezomib-triggered upregulation of p38 MAPK and Hsp27 phosphorylation, thereby enhancing cytotoxicity and caspase activation. BIRB 796 downregulates IL-6 and VEGF secretion in BMSCs triggered by TNF-α and TGF-β1. [4] BIRB-796 has a pyrazole scaffold that places a lipophilic t-butyl group into the lower selectivity site and a tolyl ring into the upper selectivity site. BIRB-796 also inhibits B-Raf and Abl with IC50 of 83 nM and 14.6 μM, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HOP-92 MnHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDQfWJKSzVyPUK0MlM5OzhizszN MkDwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
NCI-H2228 NUTZ[3pVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJ|Lk[2Olgh|ryP M3PMc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
CAPAN-1 NFfSWIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfvRmNKSzVyPUKyMlE5QDRizszN M3;wWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
SK-MEL-1 NHPqVYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInBendKSzVyPUKwMlM3QDNizszN MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
DB NVPBdFlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7JfoNTUUN3ME2xPE44QTJ|IN88US=> M1PwU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
AN3-CA Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTF6LkGg{txO NUHKXXg5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
EW-13 MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEmyWohKSzVyPUG3Mlk2OTZizszN NX7IT5JFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
LC-2-ad MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTF5LkSzOlYh|ryP NXnTUZduRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
ES8 NF;iRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H6e2lEPTB;MUeuNVY4KM7:TR?= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
NCI-H1581 NF\q[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPmfWRKSzVyPUG3MlA1PDdizszN M{PqRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
HMV-II MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTUTWM2OD1zND6yN|A6KM7:TR?= MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
BEN M3:1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PQd2lEPTB;MUOuNVI3PCEQvF2= M{mwVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
NBsusSR MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7sOnhKSzVyPUGwMlgzOzVizszN M3nnTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
MS-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTvRWlKSzVyPUGwMlgzOzVizszN NIjmXGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
BFTC-905 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnraTWM2OD1zMD6xNlM{KM7:TR?= NHrqeYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
NCI-SNU-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2T0RWlEPTB;OT6wOlc{QSEQvF2= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
MPP-89 NGPzW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjINpFiUUN3ME24MlQ3OjVzIN88US=> MkTlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
T-24 NG[zfmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Hkb2lEPTB;OD60NFY4OyEQvF2= MlzkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
KP-N-YN NE\ZbFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRThwMkCxPUDPxE1? M3j1cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
IST-MES1 MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTdwOUW2N|ch|ryP Mn3jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
NCI-H358 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTdwNUO4JO69VQ>? M4jnR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
GOTO M4DkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\Qd4IyUUN3ME22MlM6OTZzIN88US=> NH2yelI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
DU-145 MkXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrpTWM2OD1|LkmzPFEyKM7:TR?= M4jnW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
EoL-1-cell Mlu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofvTWM2OD1yLkO0O|Y{KM7:TR?= MkfGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
KYSE-270 NYrJT|VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHtVWdKSzVyPUK0MlU2PzNizszN NYHaUVI2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
HCC1806 NHTuPZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJ2Lke3PVkh|ryP NFPxfGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
HuO-3N1 M1v6Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjoTWM2OD1{NT64NVg2KM7:TR?= NGrIb5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
HOS MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF30WI1KSzVyPUK1MlkzQTJizszN MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
KYSE-510 M2jiTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETVU2ZKSzVyPUK2MlE3OTJizszN M1ryR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
COLO-741 NGjIdI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3vZ4RKSzVyPUK2MlM{OjlizszN NF3NVoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
H-EMC-SS M4n3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXyTWM2OD1{Nj65NlQ2KM7:TR?= Mn7tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
HCC1937 NGHxOIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3yzVWlEPTB;MkeuNlI{QCEQvF2= MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
NCI-H2126 MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2iyVGlEPTB;MkeuN|k4PSEQvF2= NGfISXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
NCI-H1703 M3;te2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHMS3pKSzVyPUK4MlA1OTNizszN M2jtZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
U-2-OS M3jQXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHe3PGdKSzVyPUK4MlU2OTVizszN MmnsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
DBTRG-05MG NETOOFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFT1UoZKSzVyPUK4MlU3PTFizszN NIfVWWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
MHH-ES-1 NYGyTYN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PFb2lEPTB;M{GuPVQyKM7:TR?= NVy3dI46RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
HCC1419 NWrPSWlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfXfJdKSzVyPUOyMlEyOTlizszN M3nYdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
HOP-62 NEPwb5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jJbGlEPTB;M{KuNlcxOSEQvF2= MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
AM-38 NWjZNI1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTN{Lkm5N|Eh|ryP MoPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
NCI-H2009 NEXiPIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLuUJl1UUN3ME2zN{41ODB5IN88US=> MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
EM-2 Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX6VJhnUUN3ME2zN{42PTFzIN88US=> MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
SW1116 MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoqxTWM2OD1|ND60PFM5KM7:TR?= MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
SK-N-AS NELt[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\EXG9vUUN3ME2zOU4xPzF2IN88US=> MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
ChaGo-K-1 MorTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTN3Lk[wN|Ih|ryP MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
RT-112 NETW[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fFcGlEPTB;M{WuPVg4QSEQvF2= MkLnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
HTC-C3 NX;6SGhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[2[2VKSzVyPUO2MlI{PTVizszN MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
SK-NEP-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTN4Lk[xNFYh|ryP NG\xXIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
LB831-BLC NHvtVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonJTWM2OD1|Nz62OVQyKM7:TR?= M13oVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
CTB-1 NHu0fFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfjXpdKSzVyPUO4MlQ2OTJizszN NFTheHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
MOLT-4 M3\zbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTN6LkizPVEh|ryP NWW2eFc6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
SW756 MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1yzb2lEPTB;NECuPVM5PSEQvF2= Moq4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
CAL-72 MkL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M171ZWlEPTB;NEKuNFMh|ryP MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
KNS-62 NFnOUVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTR{Lk[yPVYh|ryP NEDmPYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
KARPAS-299 M{XFe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1y0SWlEPTB;NEOuN|I{OyEQvF2= M2PTOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
HEL MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zBPWlEPTB;NEWuOFY1PiEQvF2= MkTmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
KP-4 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjVOnhKSzVyPUS2Mlc{PjFizszN NEXEeGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
NEC8 M3PtVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHkUJI3UUN3ME20O{4yPjZzIN88US=> NVHMdJRMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
G-402 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzrTWM2OD12OD63NFEzKM7:TR?= NVjY[JVMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
Sf21 NIHoOlRHfW6ldHnvckBie3OjeR?= MoDhRolv\GmwZzDh[oZqdmm2eTD0c{B4cWymIIT5dIUhcHWvYX6gZolwfGmwIHzhZoVtdGWmIICzPEBidHCqYTCoPUB1dyB|NUKgdoV{cWS3ZYOpJIV5eHKnc4Pl[EBqdiC|ZkKxJIlve2WldDDj[YxteyCVUGKgZY5idHm|aYOsJGtlKD1iMD6wNFAyOjNizszNMi=> NXH1VnR1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4N|Q1OzFpPkK4PFM1PDNzPD;hQi=>
THP1 NEfNUoVHfW6ldHnvckBie3OjeR?= NXLzZmltUW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EBVVk[jbIDoZUBxem:mdXP0bY9vKGmwIHj1cYFvKFSKUEGgZ4VtdHNuIFnDOVAhRSByLkCxN{DPxE1w NH3Me289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOyOVc3QCd-MUizNlU4Pjh:L3G+
U937 MmLkRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>? M4HMUVIhcHK| NXT3cIRYSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCmaX\m[ZJmdnSrYYTl[EBpfW2jbjDVPVM4KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gUHBUNWmwZIXj[YQhXE6IYXzwbIEheHKxZIXjeIlwdiCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KEySUz3zeIlufWyjdHnvckBnd3JiNDDodpMh[nlic3Hu[Jdq[2hiRVzJV2EhemWuYYTpeoUhfG9idnXobYNt\S22cnXheIVlKGOxboTyc4wtKEmFNUCgQUAxNjBzNTFOwG0v M3PXU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OECwN|A6Lz5{NkiwNFMxQTxxYU6=
THP1 MYfGeY5kfGmxbjDhd5NigQ>? NF7MO2FKdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJHRPTmGucHjhJJBzd2S3Y4Tpc44hcW5iaIXtZY4hXEiSMTDj[YxteyxiSVO1NEA:KDBwMEG4JO69VS5? NVW3d2VoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzOVY6OjlpPkG5N|U3QTJ7PD;hQi=>
THP1 NYT0SoRTTnWwY4Tpc44h[XO|YYm= NXzBZ2x[UW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EB1fW2xcjDu[YNzd3OrczDmZYN1d3JvYXzwbIEhMFSQRj3hcJBp[SlicILv[JVkfGmxbjDpckBVUFBvMTDj[YxteyxiRVO1NEA:KDBwMEG4JO69VS5? MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjB6NkS4OUc,OTJyOE[0PFU9N2F-
THP M3TBR2Z2dmO2aX;uJIF{e2G7 MkDkWIV{fGWmIH\vdkBqdmirYnn0bY9vKG:oIGT1cY9zKG6nY4Lvd4l{KG[jY4Tvdkwh[WyyaHGgbY4hXEiSIHPlcIx{NCCHQ{WwJF0hOC5yMUig{txONg>? MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDV4MUC4O{c,OTR3NkGwPFc9N2F-
THP1 M2rLemZ2dmO2aX;uJIF{e2G7 NUL0VGx6UW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EBVVk[jbIDoZUBxem:mdXP0bY9vKGmwIGTIVFEh[2WubIOsJGlEPTBiPTCwMlAyQCEQvF2u NGXqNlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2NFExQCd-MUe1OlAyODh:L3G+
THP1 MWPGeY5kfGmxbjDhd5NigQ>? NXKzR2ZLUW6qaXLpeIlwdiCxZjDMVHMue3SrbYXsZZRm\CCWTl\hcJBp[SCycn;keYN1cW:wIHnuJIh2dWGwIGTIVFEh[2WubIOsJGlEPTBiPTCwMlAyQCEQvF2u M1PqOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NE[yPVQxLz5zOES2Nlk1ODxxYU6=
HLF M3zZcGZ2dmO2aX;uJIF{e2G7 MUHJcohq[mm2aX;uJI9nKHB|OHHsdIhiKHCqb4PwbI9zgWyjdHnvckBqdiCLTD2xMYFteGijLYP0bY12dGG2ZXSgTGxHKGOnbHzzMEBKSzVyIE2gNE4xPDdizszNMi=> MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZyMkK2Nkc,OTh4MEKyOlI9N2F-
HLF MUXGeY5kfGmxbjDhd5NigQ>? M1\aZWlvcGmkaYTpc44hd2ZiSGPQNlcheGixc4Doc5J6dGG2aX;uJIlvKEmOLUGtZYxxcGFvc4TpcZVt[XSnZDDIUGYh[2WubIOsJGlEPTBiPTCwMlA2QCEQvF2u MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZyMkK2Nkc,OTh4MEKyOlI9N2F-
HEK293F M4TtUmZ2dmO2aX;uJIF{e2G7 MoLvTY5pcWKrdHnvckBw\iC|b3TpeY0h[XK|ZX7heIUh[WO2aY\heIVlKE5vdHXycYlv[WxiR2PUMZRi\2enZDDCdpVocWFibXHsZZlqKE2SS{Gg[ZhxemW|c3XkJIlvKEiHS{K5N2Yh[2WubIOgeZNqdmdiRlHNMZA{QHSrZHWgZZMhe3Wkc4TyZZRmKGK7IFnNRXAh[XO|YYmsJGlEPTBiPTCwMlE1KM7:TT6= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV2MUO2Nkc,Ojl3NEGzOlI9N2F-
BL21(DE3) NHrYdJRHfW6ldHnvckBie3OjeR?= M2XLeGlvcGmkaYTpc44hd2ZicEO4ZYxxcGFiYXP0bZZmKG[xcn2g[ZhxemW|c3XkJIlvKEW|Y3jldolkcGmjIHPvcIkhSkx{MTjESVMqKGOnbHzzJIJ6KEiWUl[gZZN{[XluIFnDOVAhRSByLkK1JO69VS5? NGXlRYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmyPFg2QCd-MUm5Nlg5PTh:L3G+
whole blood cells NWrRdpBtSW62aXnu[oxidW2jdH;yfUBie3OjeR?= NVj0[Wl3PCCqcoO= MUDBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJIh2dWGwIIfoc4xmKGKub3;kJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgWG5H[WyyaHGgdJJw\HWldHnvckBi\nSncjC0JIhzeyCkeTD0bY1mNXKnc3;seoVlKG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwNjFOwG0v NVnPeJhFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3OFkzQDJpPkKyO|Q6Ojh{PD;hQi=>
A673 NIW1S5lyUFSVIHHzd4F6 MWHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>? M1z5c|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY M{\IbZFJXFNiYYPzZZk> M{PlN5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy| NHPZeHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD MYrxTHRUKGG|c3H5 Ml65dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{ Ml75QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH M2TFNZFJXFNiYYPzZZk> NH;QZpRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=> MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MG 63 (6-TG R) MnrtdWhVWyCjc4PhfS=> Mn7VdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| NETBSWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 NUHPXohoeUiWUzDhd5NigQ>? NYjwe2hXeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=> M2PMSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC MXzxTHRUKGG|c3H5 NEn2bldyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> MlrFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-p38 / p38 ; 

PubMed: 23349819     


The inhibitory effect of phosphorylated p38 in KB, KBV200 (B) and in MCF-7, MCF-7/ADR (C) treated with BIRB796 at various concentrations after 24 h. 

mTOR / p-S6K / S6K / p-MK2 / MK2 / p-Hsp27 / Hsp27 ; 

PubMed: 26844273     


CRC cells were treated with 4 μM LY2228820, 10 μM BIRB796 or 10 μM SB202190 for 2 h and p38 and mTORC1 signaling was analyzed by immunoblot.

p-p38 / γ-H2AX ; 

PubMed: 27082306     


The expression of p-P38 was tested via protein gel blot after the cells were treated with BIRB796.

23349819 26844273 27082306
In vivo BIRB 796 (30 mg/kg) inhibits 84% of TNF-α in LPS-stimulated mice and demonstrates efficacy in a mouse model of established collagen-induced arthritis. [1] BIRB 796 has good pharmacokinetic performance even after oral administration in mice. [2]

Protocol

Animal Research:

[2]

- Collapse
  • Animal Models: Collagen-induced arthritis in female Balb/c mice
  • Dosages: 1 mg/kg (intravenous) or 10 mg/kg (oral)
  • Administration: Intravenous injection or by oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (189.51 mM)
Ethanol 100 mg/mL (189.51 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40%PEG300+5%Tween80 +50%H2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 527.66
Formula

C31H37N5O3

CAS No. 285983-48-4
Storage powder
in solvent
Synonyms N/A
Smiles CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OCCN5CCOCC5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products

Tags: buy Doramapimod (BIRB 796) | Doramapimod (BIRB 796) supplier | purchase Doramapimod (BIRB 796) | Doramapimod (BIRB 796) cost | Doramapimod (BIRB 796) manufacturer | order Doramapimod (BIRB 796) | Doramapimod (BIRB 796) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID